Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial

Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, View ORCID ProfileAartjan J. W. te Velthuis
doi: https://doi.org/10.1101/2021.01.05.21249237
Olha Holubovska
1O.O. Bogomolets National Medical University, T. Shevchenko blvd., 13, Kyiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denisa Bojkova
2Institute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Elli
3Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”, Via Giuseppe Colombo 81, 20133 Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Bechtel
2Institute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Boltz
4IIT Research institute, 10 W 35th St, Chicago, IL 60616, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Muzzio
4IIT Research institute, 10 W 35th St, Chicago, IL 60616, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinjian Peng
4IIT Research institute, 10 W 35th St, Chicago, IL 60616, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederico Sala
3Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”, Via Giuseppe Colombo 81, 20133 Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cesare Cosentino
3Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”, Via Giuseppe Colombo 81, 20133 Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alla Mironenko
5L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Department of respiratory and other viral infections, Amosova str 5a, 03083, Kyiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Milde
6Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuriy Lebed
7Pharmaxi LLC, Filatova Str., 10A, office 3/20, 01042, Kyiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holger Stammer
6Pharmalog Institut für klinische Forschung GmbH, Ismaning, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Goy
8Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Guerrini
3Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”, Via Giuseppe Colombo 81, 20133 Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutz Mueller
9Dr. Regenold GmbH, Zöllinplatz 4, D-79410 Badenweiler, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ajwt6@cam.ac.uk cinatl@em.uni-frankfurt.de lutz.mueller@regenold.com v.margitich@farmak.ua
Jindrich Cinatl
2Institute of Medical Virology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ajwt6@cam.ac.uk cinatl@em.uni-frankfurt.de lutz.mueller@regenold.com v.margitich@farmak.ua
Victor Margitich
8Farmak Joint Stock Company, Kyrylivska Street, 04080, Kyiv, Ukraine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ajwt6@cam.ac.uk cinatl@em.uni-frankfurt.de lutz.mueller@regenold.com v.margitich@farmak.ua
Aartjan J. W. te Velthuis
10Division of Virology, Department of Pathology, Addenbrooke’s Hospital, University of Cambridge, Hills Road, CB2 2QQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aartjan J. W. te Velthuis
  • For correspondence: ajwt6@cam.ac.uk cinatl@em.uni-frankfurt.de lutz.mueller@regenold.com v.margitich@farmak.ua
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon®) is an orally active inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. Here we show that enisamium can inhibit SARS-CoV-2 infections in NHBE and Caco-2 cells. In vitro, the previously identified enisamium metabolite VR17-04 directly inhibits the activity of the SARS-CoV-2 RNA polymerase. Docking and molecular dynamics simulations suggest that VR17-04 prevents GTP and UTP incorporation. To confirm enisamium’s antiviral properties, we conducted a double-blind, randomized, placebo-controlled trial in adult, hospitalized COVID-19 patients, which needed medical care either with or without supplementary oxygen. Patients received either enisamium (500 mg per dose) or placebo for 7 days. A pre-planned interim analysis showed in the subgroup of patients needing supplementary oxygen (n = 77) in the enisamium group a mean recovery time of 11.1 days, compared to 13.9 days for the placebo group (log-rank test; p=0.0259). No significant difference was found for all patients (n = 373) or those only needing medical care (n = 296). These results thus suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and that enisamium treatment shortens the time to recovery for COVID-19 patients needing oxygen.

Significance statement SARS-CoV-2 is the causative agent of COVID-19. Although vaccines are now becoming available to prevent SARS-CoV-2 spread, the development of antivirals remains necessary for treating current COVID-19 patients and combating future coronavirus outbreaks. Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro. Moreover, we find that COVID-19 patients requiring supplementary oxygen, recover more quickly than patients treated with a placebo. Enisamium may therefore be an accessible treatment for COVID-19 patients.

Competing Interest Statement

V.M. and A.G. are employees of Farmak Public Joint Stock Company, Kiev, Ukraine. Part of the research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.

Clinical Trial

NCT04682873

Funding Statement

A.J.W.t.V is supported by joint Wellcome Trust and Royal Society grant 206579/Z/17/Z and the National Institutes of Health grant R21AI147172. Part of this research was funded by Farmak Public Joint Stock Company, Kiev, Ukraine.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethics Commission of the Regional Clinical Hospital of Ivano-Frankivsk Regional Council on 12.05.2020. The registration number of the study in ClinicalTrials.gov is NCT04682873.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data will be made available on ClinicalTrials.gov via number NCT04682873 and via the provided supplemental information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
medRxiv 2021.01.05.21249237; doi: https://doi.org/10.1101/2021.01.05.21249237
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
medRxiv 2021.01.05.21249237; doi: https://doi.org/10.1101/2021.01.05.21249237

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5219)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1995)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)